gantenerumab
mAbexperimental
Gantenerumab is a monoclonal antibody for the treatment of Alzheimer's disease being developed by Hoffmann-La Roche pharmaceuticals. — Wikipedia
Clinical trial activity
23 trials · 9 clinical orgs · 0 marketing orgs
Phase 1
9
Phase 2
11
Phase 3
13
Phase 4
0
Earliest trial started Dec 1, 2006 (NCT00531804)
Timeline
Indications
Mechanism of action
- Beta amyloid A4 proteinBINDING AGENT
Beta amyloid A4 protein binding agent
Binds with sub-nanomolar affinity to a conformational epitope expressed on amyloid-ß fibrils. Neutralises disease-relevant aggregated forms of amyloid-beta.
- Beta amyloid A4 proteinINHIBITOR
APP inhibitor
APP other
Binds with sub-nanomolar affinity to a conformational epitope expressed on amyloid-ß fibrils. Neutralises disease-relevant aggregated forms of amyloid-beta.
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaGantenerumab ↗
- ChEMBLCHEMBL5095377 ↗
- ChEMBLCHEMBL1743025 ↗
Also known as
- gantenerumab
- gantenerumab
- gantenerumab
- r-1450
- rg-1450
- ro-4909832
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07170150 | Phase 3 | Nov 12, 2025 | Roche |
| NCT07169578 | Phase 3 | Sep 17, 2025 | Roche |
| NCT05552157 | Phase 2/Phase 3 (Phase 3) | Dec 2, 2022 | Alzheimer's Association, Genentech, National Institute on Aging (NIA), Roche, Washington University in St. Louis |
| NCT05256134 | Phase 3 | Apr 19, 2022 | Roche |
| NCT04639050 | Phase 1/Phase 2 (Phase 2) | Mar 18, 2021 | Roche |
| NCT04592341 | Phase 2 | Dec 31, 2020 | Roche |
| NCT04374253 | Phase 3 | Aug 3, 2020 | Roche |
| NCT06424236 | Phase 2/Phase 3 (Phase 3) | Jun 30, 2020 | Alzheimer's Association, National Institute on Aging (NIA), Roche, Washington University in St. Louis |
| NCT04339413 | Phase 3 | May 19, 2020 | Roche |
| NCT04023994 | Phase 1 | Aug 3, 2019 | Roche |
| NCT03444870 | Phase 3 | Jun 6, 2018 | Roche |
| NCT03443973 | Phase 3 | Jun 6, 2018 | Roche |
| NCT03236844 | Phase 1 | Aug 1, 2017 | Roche |
| NCT02882009 | Phase 1 | Aug 31, 2016 | Roche |
| NCT02711423 | Phase 1 | Mar 31, 2016 | Roche |
| NCT02133937 | Phase 1 | Apr 1, 2014 | Roche |
| NCT02051608 | Phase 3 | Mar 1, 2014 | Roche |
| NCT04623242 | Phase 2/Phase 3 (Phase 3) | Dec 31, 2012 | Accelerating Medicines Partnership, Alzheimer's Association, Avid Radiopharmaceuticals, Eli Lilly, National Institute on Aging (NIA), Roche, Washington University in St. Louis |
| NCT01760005 | Phase 2/Phase 3 (Phase 3) | Dec 1, 2012 | Accelerating Medicines Partnership, Alzheimer's Association, Avid Radiopharmaceuticals, Eli Lilly, National Institute on Aging (NIA), Roche, Washington University in St. Louis |
| NCT01656525 | Phase 1 | Jun 1, 2012 | Chugai |
Showing 20 of 23 trials
Page 1 / 2
Organizations
Research & Development (9)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Roche | For profit | 22 | 18 | 3 | 2006 |
| Alzheimer's Association | Academic/Hospital | 4 | 0 | 1 | 2012 |
| National Institute on Aging (NIA) | Government | 4 | 0 | 1 | 2012 |
| Washington University in St. Louis | Academic/Hospital | 4 | 4 | 1 | 2012 |
| Accelerating Medicines Partnership | Academic/Hospital | 2 | 0 | 1 | 2012 |
| Avid Radiopharmaceuticals | For profit | 2 | 0 | 1 | 2012 |
| Eli Lilly | For profit | 2 | 0 | 1 | 2012 |
| Chugai | For profit | 1 | 1 | 1 | 2012 |
| Genentech | For profit | 1 | 0 | 1 | 2022 |
9 organizations
Page 1 / 1